CRISPR Therapeutics to Present at the Guggenheim Inaugural Healthcare Innovation Conference
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company specializing in gene-based medicines, has announced that their CEO and Chairman, Samarth Kulkarni, Ph.D., will present at the Guggenheim Inaugural Healthcare Innovation Conference. The presentation is scheduled for Tuesday, November 12, 2024, at 2:00 p.m. ET.
A live webcast of the fireside chat will be accessible through the company's website's 'Events & Presentations' page in the Investors section. The webcast recording will remain available for 14 days after the presentation.
CRISPR Therapeutics (Nasdaq: CRSP), un'azienda biofarmaceutica specializzata in medicinali basati sui geni, ha annunciato che il loro CEO e Presidente, Samarth Kulkarni, Ph.D., presenterà alla Guggenheim Inaugural Healthcare Innovation Conference. La presentazione è prevista per martedì 12 novembre 2024, alle 14:00 ET.
Un webcast in diretta della chiacchierata sarà accessibile attraverso la pagina 'Eventi e Presentazioni' del sito web dell'azienda nella sezione Investitori. La registrazione del webcast sarà disponibile per 14 giorni dopo la presentazione.
CRISPR Therapeutics (Nasdaq: CRSP), una empresa biofarmacéutica especializada en medicinas basadas en genes, ha anunciado que su CEO y Presidente, Samarth Kulkarni, Ph.D., presentará en la Guggenheim Inaugural Healthcare Innovation Conference. La presentación está programada para el martes 12 de noviembre de 2024, a las 2:00 p.m. ET.
Una transmisión en vivo de la charla estará disponible a través de la página 'Eventos y Presentaciones' del sitio web de la empresa en la sección de Inversores. La grabación de la transmisión estará disponible durante 14 días después de la presentación.
CRISPR Therapeutics (Nasdaq: CRSP)는 유전자 기반 의약품을 전문으로 하는 생명공학 회사로, CEO이자 회장인 Samarth Kulkarni 박사가 구겐하임 기념 헬스케어 혁신 회의에서 발표할 것이라고 발표했습니다. 발표는 2024년 11월 12일 화요일 오후 2시(ET)에 예정되어 있습니다.
화상 대담의 생중계는 회사 웹사이트의 투자자 섹션에 있는 '이벤트 및 발표' 페이지를 통해 접근할 수 있습니다. 화상 대담 녹화는 발표 후 14일 동안 이용할 수 있습니다.
CRISPR Therapeutics (Nasdaq: CRSP), une entreprise biopharmaceutique spécialisée dans les médicaments basés sur les gènes, a annoncé que son PDG et Président, Samarth Kulkarni, Ph.D., présentera à la Guggenheim Inaugural Healthcare Innovation Conference. La présentation est prévue pour le mardi 12 novembre 2024, à 14h00 ET.
Une diffusion en direct du chat sera accessible via la page 'Événements & Présentations' du site Web de l'entreprise dans la section Investisseurs. L'enregistrement de la diffusion restera disponible pendant 14 jours après la présentation.
CRISPR Therapeutics (Nasdaq: CRSP), ein biopharmazeutisches Unternehmen, das sich auf genbasierte Arzneimittel spezialisiert hat, hat angekündigt, dass ihr CEO und Vorsitzender, Samarth Kulkarni, Ph.D., auf der Guggenheim Inaugural Healthcare Innovation Conference präsentieren wird. Die Präsentation ist für Dienstag, den 12. November 2024, um 14:00 Uhr ET geplant.
Eine Live-Übertragung des Fireside-Chats ist über die Seite 'Veranstaltungen & Präsentationen' auf der Unternehmenswebsite im Bereich Investoren zugänglich. Die Aufzeichnung des Webcasts bleibt 14 Tage nach der Präsentation verfügbar.
- None.
- None.
ZUG, Switzerland and BOSTON, Nov. 07, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that Samarth Kulkarni, Ph.D., Chief Executive Officer and Chairman of CRISPR Therapeutics, will present at the Guggenheim Inaugural Healthcare Innovation Conference on Tuesday, November 12, 2024, at 2:00 p.m. ET.
A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events. A replay of the webcast will be archived on the Company's website for 14 days following the presentation.
About CRISPR Therapeutics
Since its inception over a decade ago, CRISPR Therapeutics has transformed from a research-stage company advancing programs in the field of gene editing, to a company that recently celebrated the historic approval of the first-ever CRISPR-based therapy and has a diverse portfolio of product candidates across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, cardiovascular, autoimmune, and rare diseases. CRISPR Therapeutics advanced the first-ever CRISPR/Cas9 gene-edited therapy into the clinic in 2018 to investigate the treatment of sickle cell disease or transfusion-dependent beta thalassemia, and beginning in late 2023, CASGEVY (exagamglogene autotemcel [exa-cel]) was approved in some countries to treat eligible patients with either of those conditions. The Nobel Prize-winning CRISPR science has revolutionized biomedical research and represents a powerful, clinically validated approach with the potential to create a new class of potentially transformative medicines. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic partnerships with leading companies including Bayer and Vertex Pharmaceuticals. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Boston, Massachusetts and San Francisco, California, and business offices in London, United Kingdom. To learn more, visit www.crisprtx.com.
(CRSP-GEN)
Investor Contact:
Susan Kim
+1-617-307-7503
susan.kim@crisprtx.com
Media Contact:
Rachel Eides
+1-617-315-4493
rachel.eides@crisprtx.com
FAQ
When is CRISPR Therapeutics (CRSP) presenting at the Guggenheim Healthcare Conference 2024?
How long will CRSP's Guggenheim Conference webcast be available for replay?
Who is presenting for CRSP at the Guggenheim Healthcare Innovation Conference 2024?
Where can I watch CRSP's Guggenheim Conference presentation?
